Literature DB >> 21037810

Inherited colorectal cancer syndromes.

Robert Gryfe1.   

Abstract

Colorectal cancer is common in the Western world; ~5% of individuals diagnosed with colorectal cancer have an identifiable inherited genetic predisposition to this malignancy. Genetic testing and rational clinical management recommendations currently exist for the management of individuals with a variety of colorectal cancer syndromes, including hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch syndrome), familial adenomatous polyposis (FAP), MYH-associated polyposis (MAP), and the hamartomatous polyposis syndromes (Peutz-Jeghers, juvenile polyposis, and Cowden disease). In addition to colorectal neoplasia, these syndromes frequently predispose carriers to a variety of extracolonic cancers. The elucidation of the genetic basis of several colorectal cancer predisposition syndromes over the past two decades has allowed for better management of individuals who are either affected with, or at-risk for inherited colorectal cancer syndromes. Appropriate multidisciplinary management of these individuals includes genetic counseling, genetic testing, clinical screening, and treatment recommendations.

Entities:  

Keywords:  Colorectal cancer; familial adenomatous polyposis; hamartomatous polyps; hereditary nonpolyposis colorectal cancer

Year:  2009        PMID: 21037810      PMCID: PMC2796102          DOI: 10.1055/s-0029-1242459

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  84 in total

1.  Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer).

Authors:  James Church; Clifford Simmang
Journal:  Dis Colon Rectum       Date:  2003-08       Impact factor: 4.585

2.  American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing.

Authors: 
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study.

Authors:  P L Barratt; M T Seymour; S P Stenning; I Georgiades; C Walker; K Birbeck; P Quirke
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

4.  Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors.

Authors:  Nada Al-Tassan; Nikolas H Chmiel; Julie Maynard; Nick Fleming; Alison L Livingston; Geraint T Williams; Angela K Hodges; D Rhodri Davies; Sheila S David; Julian R Sampson; Jeremy P Cheadle
Journal:  Nat Genet       Date:  2002-01-30       Impact factor: 38.330

5.  Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC.

Authors:  S J Laken; G M Petersen; S B Gruber; C Oddoux; H Ostrer; F M Giardiello; S R Hamilton; H Hampel; A Markowitz; D Klimstra; S Jhanwar; S Winawer; K Offit; M C Luce; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

6.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

7.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

8.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.

Authors:  Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

10.  Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach.

Authors:  J J P Gille; F B L Hogervorst; G Pals; J Th Wijnen; R J van Schooten; C J Dommering; G A Meijer; M E Craanen; P M Nederlof; D de Jong; C J McElgunn; J P Schouten; F H Menko
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  6 in total

1.  One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study.

Authors:  Cornelia M Ulrich; Mary Playdon; Rama Kiblawi; Andreana N Holowatyj; Biljana Gigic; Stefanie Brezina; Anne J M R Geijsen; Jennifer Ose; Tengda Lin; Sheetal Hardikar; Caroline Himbert; Christy A Warby; Jürgen Böhm; Martijn J L Bours; Fränzel J B van Duijnhoven; Tanja Gumpenberger; Dieuwertje E Kok; Janna L Koole; Eline H van Roekel; Petra Schrotz-King; Arve Ulvik; Andrea Gsur; Nina Habermann; Matty P Weijenberg; Per Magne Ueland; Martin Schneider; Alexis Ulrich
Journal:  Br J Nutr       Date:  2020-02-05       Impact factor: 3.718

2.  Colorectal cancer in a monoallelic MYH mutation carrier.

Authors:  Racha Khalaf; Christopher Jones; Warren Strutt; Paul Williamson
Journal:  J Gastrointest Surg       Date:  2013-04-27       Impact factor: 3.452

3.  Identification of patients at risk for hereditary colorectal cancer.

Authors:  Nitin Mishra; Jason Hall
Journal:  Clin Colon Rectal Surg       Date:  2012-06

Review 4.  Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways.

Authors:  Alessia Parascandolo; Mikko O Laukkanen
Journal:  Antioxid Redox Signal       Date:  2018-11-22       Impact factor: 8.401

Review 5.  Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.

Authors:  Christina C Pierre; Shawn M Hercules; Clayton Yates; Juliet M Daniel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 11.414

6.  Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer.

Authors:  David J Bautz; Ang T Sherpa; David W Threadgill
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.